Clinical Trials Using Afatinib Dimaleate

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Afatinib Dimaleate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-9 of 9
  • Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

    This randomized phase II / III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether afatinib dimaleate is more effective when given alone or with cetuximab in treating patients with non-small cell lung cancer.
    Location: 562 locations

  • Afatinib Dimaleate and Paclitaxel in Treating Patients with Trastuzumab-Refractory Metastatic Esophagus or Stomach Cancer

    This phase II trial studies how well afatinib dimaleate and paclitaxel work in treating patients with esophagus or stomach cancer that has come back after being treated with trastuzumab or spread to other places in the body. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving afatinib dimaleate with paclitaxel may work better in treating patients with esophagus or stomach cancer.
    Location: 8 locations

  • Afatinib Dimaleate and Radiation Therapy with or without Docetaxel in Treating Patients with Head and Neck Cancer Previously Treated with Surgery

    This phase I trial studies the side effects and best dose of afatinib dimaleate when given together with radiation therapy with or without docetaxel in treating patients with head and neck cancer previously treated with surgery. Afatinib dimaleate and docetaxel may stop the growth of head and neck cancer by blocking blood flow to the tumor or by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. It is not yet known whether afatinib dimaleate with radiation therapy works better with or without docetaxel in treating head and neck cancer.
    Location: 4 locations

  • Afatinib Dimaleate, Combination Chemotherapy, and Radiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer

    This phase II trial studies how well afatinib dimaleate works when given together with combination chemotherapy and radiation therapy in treating patients with stage III non-small cell lung cancer. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving afatinib dimaleate together with combination chemotherapy and radiation therapy may kill more tumor cells.
    Location: 3 locations

  • Afatinib Dimaleate and Capecitabine in Treating Patients with Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

    This phase I / Ib trial studies the side effects and best dose of afatinib dimaleate when given together with capecitabine in treating patients with solid tumors, pancreatic cancer, or biliary cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment and has not responded to previous treatment. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving afatinib dimaleate together with capecitabine may be a better treatment for solid tumors, pancreatic cancer, or biliary cancer.
    Location: 2 locations

  • Afatinib Dimaleate in Treating Patients with Advanced Refractory Urothelial Cancer

    This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that has not responded to previous treatment (refractory). Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Afatinib Dimaleate and Cetuximab as Second-Line Treatment in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer

    This phase II trial studies how well afatinib dimaleate and cetuximab work as second-line treatment in treating patients with head and neck squamous cell cancer that has come back or has spread to other parts of the body. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may interfere with the ability of tumor cells to grow and spread. Giving afatinib dimaleate and cetuximab may work better in treating patients with head and neck squamous cell cancer.
    Location: 2 locations

  • Pembrolizumab and Afatinib Dimaleate in Treating Patients with Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer with Resistance to Erlotinib Hydrochloride

    This phase I / Ib trial studies the side effects and best dose of pembrolizumab when given together with afatinib dimaleate in treating patients with non-small cell lung cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment, or has come back and does not respond to erlotinib hydrochloride. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and afatinib dimaleate together may be a better treatment for non-small cell lung cancer.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Afatinib Expanded Access Program

    This is an open-label, multi-center, single-arm trial, designed to provide early access to afatinib and to provide additional information on the safety and efficacy of afatinib in advanced NSCLC patients who harbor an EGFR mutation.
    Location: Location information is not yet available.